Background: Mortality rates due to massive pulmonary embolism (PE) are much higher than estimated. Although thrombolytic therapy is controversial, it can be a life-saving procedure and can be safely used in patients with massive PE. Study aim: We aimed to share the results of thrombolytic treatment in patients with massive PE. Material and methods: We retrospectively evaluated 72 patients with PE admitted between Turkey. The data of patients who received thrombolytic treatment were retrospectively analyzed. Results: The female to male ratio was 24/48, with a mean age of 62.7 ± 12.6 (minimum 27, maximum 88) years. The diagnosis of massive PE was established with echocardiography in all patients and was confirmed via pulmonary CT angiography in 45 patients (62.5%) who presented an appropriate clinical status for this imaging technique. The most common symptoms were dyspnea (90.3%), chest pain (83.3%), and syncope (40.2%). The S1Q3T3 electrocardiography pattern was noted in 82% of patients, who rapidly recovered after thrombolytic therapy. Cardiopulmonary arrest was seen in 25 patients (37.2%), and thrombolytic treatment was administered during cardiopulmonary resuscitation in 18% (n = 13) of patients. The survival rate was 30.7% (n = 4) in patients with cardiopulmonary arrest who received thrombolytic treatment in the emergency room. The complications of rt-PA treatment included minor hemorrhages in 6.4% (n = 5), major hemorrhages in 2.7% (n = 2), and allergic reactions in 1.3% (n = 1) of patients. None of the patients had deceased as a complication of thrombolytic treatment. The overall mortality rate was 26.2% (n = 19), and 12.5% (n = 9) of the patients have died in first 24 hours after thrombolysis. Conclusions: We concluded that the risk factors, ECG, and echocardiography are key indicators for the suspicion of massive PE in patients with hemodynamic shock. Based on our experience, early thrombolytic therapy is a life-saving intervention in patients with diagnosed and/or suspected massive PE.
INTRODUCTION
Pulmonary embolism (PE) is increasingly recognized as a cause of significant morbidity and mortality. Patients with PE are commonly classified into massive (high-risk), submassive (intermediate-risk), and low-risk PE to help determine the required treatment. Risk stratification scores are used to determine the risk of complications and associated mortality. Massive or high-risk PE is defined as suspected or confirmed PE in the presence of shock, sustained hypotension, absence of peripheral pulse, or persistent profound bradycardia. Submassive PE is defined as suspected or confirmed PE with right ventricular dysfunction in the absence of shock. 1, 2 According to various studies, the rates of mortality due to massive PE are much higher than estimated, and alteplase can be safely used in patients with massive PE for thrombolysis. 3, 4 We aimed to share the results of thrombolytic treatment in patients with high-risk PE.
MATERIALS AND METHODS
We retrospectively evaluated patients admitted with PE between January 2010 and April 2018 in the Department of Pulmonary Medicine, VM Medicalpark Samsun Hospital, Samsun, Turkey. The data of patients who received thrombolytic treatment were retrospectively analyzed.
The diagnosis of PE and patient selection for thrombolytic treatment were decided on using the following criteria:
(1) patients aged over 17 years with symptoms suggestive of acute massive PE; (2) massive PE defined as acute PE with sustained hypotension (systolic blood pressure <90 mmHg for at least 15 minutes or requiring inotropic support, not due to a cause other than PE such as arrhythmia, hypovolemia, sepsis, or left ventricular dysfunction), pulselessness, or persistent profound bradycardia (heart rate <40 bpm with signs or symptoms of shock).
In addition, acute right ventricular (RV) dilation, hypokinesia, and acute pulmonary arterial hypertension with paradoxical movement of the interventricular septum on echocardiography were added as criteria for thrombolytic treatment in patients with hemodynamic instability and/ or cardiopulmonary arrest; (3) PE confirmed with contrast-enhanced thorax computed tomography (CT) in appropriate patients.
TreaTmenT plan
Alteplase (rt-PA, Actilyse®; Boehringer Ingelheim, Ingelheim, Germany) was administered via the following ther-apeutic protocol: 10 mg bolus via a central venous line and 90 mg continuous infusion over 2 hours. All patients were continuously monitored for heart rate, systolic, diastolic, and mean systemic blood pressures, and oxygen saturation with a pulse oximeter.
The study was performed in accordance with the ethical principles in the Good Clinical Practice (GCP) guidelines and applicable local regulatory requirements, and the protocol was approved by local ethics review boards.
All the patients read the patient information form about the study procedure and written informed consent was obtained.
RESULTS
A total of 72 patients were diagnosed as high-risk PE and treated with alteplase (rt-PA). The characteristics of the study population and treatment results are presented in Table 1 . The female to male ratio was 24/48. The mean age of the included patients was 62.7 ± 12.6 (minimum 27, maximum 88) years. The diagnosis of massive PE was established with echocardiography in all patients and was confirmed via pulmonary CT angiography in 45 patients (Figures 1-6 ). Most common symptoms were dyspnea (90.3%), chest pain (83.3%), and syncope (40.2%). The S1Q3T3 pattern was noted in 82% of patients on the 12-lead electrocardiography, which rapidly recovered after thrombolytic therapy ( Figure 5 ). The diagnostic approach used in our institution is shown in 
DISCUSSIONS
The effect of thrombolytic therapy on mortality and the frequency of recurrent thromboembolism remain ques- Our study also assessed the rate of complications due to thrombolysis, including major (2.7%) and minor bleeding (6.4%) as well as allergic reactions (1.3%), while none of the study subjects had deceased due to administration of thrombolytic treatment. The overall mortality rate was 26.2% in the study population, and 12.5% within the first 24h after thrombolysis.
In a previous publication, we have reported a case series which included patients with massive PE who had been administered thrombolysis during cardiopulmonary resuscitation. 3 In the case series, the mortality rate was 50%, with higher rates of minor bleeding (14%) but with no major hemorrhagic complications. Furthermore, the thrombolytic treatment was not associated with any fatal hemorrhage complication. 3 Despite its low sensitivity and specificity, ECG tracing adds diagnostic value in determining the extent of the thrombotic burden and supporting the finding of right ventricular dysfunction as seen by echocardiography.
Sinus tachycardia, supraventricular tachyarrhythmias, S1Q3T3 pattern, new complete or incomplete right bundle branch block, and P pulmonale are some of the ECG patterns described in association with PE. In the PIOPED database, 30% of patients were noted to have a normal ECG, but the most common ECG finding was noted to be non-specific abnormalities of the ST segment or T wave in 49% of their population. Inverted T waves in leads V1-V4 may be present, especially in the setting of massive PE. In one study, this pattern was shown to correlate with the severity of PE. 7, 8 The most common symptoms were dyspnea (90.3%), chest pain (83.3%), and syncope (40.2%). The S1Q3T3 pattern was noted in 82% of patients on the ECG tracings.
Also, we noted that the S1Q3T3 pattern had rapidly im- are comparable for predicting 30-day mortality. [14] [15] [16] [17] [18] These results were consistent with our study. We found that the diagnostic accuracy of thoracic CT in identifying RV dysfunction on the basis of a RV/LV diameter ratio >1.0 was 95% as related to echocardiography.
CONCLUSIONS
We concluded that risk factors, ECG, and echocardiography are key indicators for the suspicion of massive PE in patients with hemodynamic shock. If there is any sign of acute PE, echocardiography should be used during cardiopulmonary arrest/instability, and alteplase should be given to patients with suspected massive PE. In patients with massive PE, mortality rates associated with thrombolytic treatment are not higher than those associated with anticoagulant therapy in the absence of thrombolytic treatment. Based on our experience, early thrombolytic therapy is a life-saving intervention in patients with diagnosed and/or suspected massive PE.
